» Authors » Yuliya Sharkovska

Yuliya Sharkovska

Explore the profile of Yuliya Sharkovska including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 368
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Geschka S, Kretschmer A, Sharkovska Y, Evgenov O, Lawrenz B, Hucke A, et al.
PLoS One . 2011 Jul; 6(7):e21853. PMID: 21789188
Background: A direct pharmacological stimulation of soluble guanylate cyclase (sGC) is an emerging therapeutic approach to the management of various cardiovascular disorders associated with endothelial dysfunction. Novel sGC stimulators, including...
12.
Kalk P, Sharkovska Y, Kashina E, von Websky K, Relle K, Pfab T, et al.
Hypertension . 2011 Feb; 57(4):755-63. PMID: 21339476
Hypertensive heart disease is a major contributor to cardiovascular mortality. Endothelin is a potent vasoconstrictive and profibrotic mediator produced by the endothelin-converting enzyme (ECE), whereas natriuretic peptides, degraded by the...
13.
Sharkovska Y, Kalk P, Lawrenz B, Godes M, Hoffmann L, Wellkisch K, et al.
J Hypertens . 2010 Jul; 28(8):1666-75. PMID: 20613628
Objectives: The nitric oxide-soluble guanylate cyclase (sGC)-cGMP signal transduction pathway is impaired in different cardiovascular diseases, including pulmonary hypertension, heart failure and arterial hypertension. Riociguat is a novel stimulator of...
14.
Kalk P, Mach A, Thone-Reineke C, Godes M, Heiden S, Sharkovska Y, et al.
Can J Physiol Pharmacol . 2008 Sep; 86(8):541-5. PMID: 18758502
Activation of the endothelin (ET) system promotes vasoconstriction, inflammation, and fibrosis in various tissues, including the lung. Therefore, ET-1 transgenic mice overexpressing ET-1 develop pulmonary fibrosis in a slow, age-dependent...